Financials in USD. Standardized financial statements.
A compact view of how West Pharmaceutical Services, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B | $1.60B | $1.51B |
| Revenue Growth? | +6.3% | -2.0% | +2.3% | +1.9% | +31.9% | +16.4% | +7.3% | +7.4% | +6.0% | 0.0% |
| Cost of Revenue? | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | $1.38B | $1.23B | $1.17B | $1.09B | $1.01B |
| Gross Profit? | $1.10B | $1.00B | $1.13B | $1.14B | $1.17B | $767.90M | $608.80M | $546.30M | $514.80M | $501.00M |
| Gross Margin? | +35.9% | +34.6% | +38.4% | +39.5% | +41.5% | +35.8% | +33.0% | +31.8% | +32.2% | +33.2% |
| Operating Expenses? | $485.90M | $407.60M | $421.80M | $375.40M | $414.70M | $348.90M | $311.60M | $291.50M | $285.10M | $285.50M |
| Operating Income? | $617.40M | $594.60M | $710.90M | $763.50M | $758.70M | $419.00M | $297.20M | $254.80M | $229.70M | $215.50M |
| EBITDA? | $723.60M | $743.80M | $844.10M | $808.10M | $879.70M | $518.90M | $403.20M | $353.20M | $326.20M | $286.90M |
| Income Before Tax | $615.30M | $600.20M | $715.70M | $700.60M | $769.00M | $418.70M | $300.70M | $248.30M | $231.60M | $198.00M |
| Income Tax Expense | $121.60M | $107.50M | $122.30M | $114.70M | $107.20M | $72.50M | $59.00M | $41.40M | $80.90M | $54.40M |
| Net Income? | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M | $346.20M | $241.70M | $206.90M | $150.70M | $143.60M |
| EPS? | $6.83 | $6.75 | $7.99 | $7.88 | $8.90 | $4.68 | $3.27 | $2.80 | $2.04 | $1.96 |
| Diluted EPS? | $6.80 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality